O-GlcNAc Modification Prevents Peptide-dependent Acceleration of α-synuclein Aggregation

Overview

Journal Chembiochem

Specialty Biochemistry

Date 2012 Nov 13

PMID 23143740

Citations 32

Authors

Nicholas P Marotta

Carli A Cherwien

Tharindumala Abeywardana

Matthew R Pratt

Affiliations

Soon will be listed here.

Abstract

Sweet relief: the Parkinson's disease- associated protein α-synuclein is post-translationally modified by N-acetylglucosamine (O-GlcNAc), but the biochemical consequences are unknown. Here we show that an O-GlcNAc-modified peptide does not participate in α-synuclein aggregation, thus suggesting that O-GlcNAc might directly inhibit aggregation in cells.

Citing Articles

O-GlcNAc participates in the meiosis of aging oocytes by mediating mitochondrial function.

Li C, Qian Z, Zhang H, Ge X, Chen L, Xue M Reproduction. 2024; 168(6).

PMID: 39405070 PMC: 11623119. DOI: 10.1530/REP-24-0138.

Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures.

Hu J, Xia W, Zeng S, Lim Y, Tao Y, Sun Y Nat Commun. 2024; 15(1):2677.

PMID: 38538591 PMC: 10973503. DOI: 10.1038/s41467-024-46898-1.

Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease.

Allen S, Meade R, White Stenner L, Mason J Mol Neurodegener. 2023; 18(1):80.

PMID: 37940962 PMC: 10633918. DOI: 10.1186/s13024-023-00675-8.

Recent development of analytical methods for disease-specific protein -GlcNAcylation.

Hu W, Zhang G, Zhou Y, Xia J, Zhang P, Xiao W RSC Adv. 2023; 13(1):264-280.

PMID: 36605671 PMC: 9768672. DOI: 10.1039/d2ra07184c.

Brain O-GlcNAcylation: From Molecular Mechanisms to Clinical Phenotype.

Uygar B, Lagerlof O Adv Neurobiol. 2022; 29:255-280.

PMID: 36255678 DOI: 10.1007/978-3-031-12390-0_9.